BASIC AND CLINICAL STUDIES ON CEFTRIAXONE (Ro 13-9904) IN THE OPHTHALMOLOGIC FIELD

• Published in: CHEMOTHERAPY Vol. 32; no. Supplement7; pp. 736 - 741
• Main Authors: OOISHI, MASAO, NAGAI, SHIGEO
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1984
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.32.Supplement7_736

The basic and clinical studies on ceftriaxone (CTRX, Ro 13-9904) for its ophthalmologic use were performed. CTRX showed an antibacterial activity against a wide range of gram-negative and -positive bacteria. The distribution of sensitivity to 20 strains of clinically isolated S. aureus was in the range from 0.78 to 12.5μg/ml with a peak at 3.13μg/ml. Twenty (20) strains of P. aeruginosa were sensitive at 6.25 to>100μg/ml with a peak at 50μg/ml. CTRX was administered intravenously at 50mg/kg into the adult white rabbit and its intraocular transfer was examined. The level in the aqueous humor reached a peak of 3.4μg/ml 30 minutes after the injection and gradually decreased to 0.76μg/ml after 6 hours. The aqueous/serum ratio at 30 minutes was 9.44%. The ocular tissue concentration at 30 minutes was high in the outer part of the eye and relatively high in the inner part. The clinical efficacy and safety of CTRX were examined in 14 cases with acute dacryocystitis, corneal ulcer, iridocyclitis purulenta, panophthalmitis and orbital infection, giving 1.0 g or 2.0 g once or twice a day by drip intravenous infusion. As results, excellent responses in 2, good in 9, fair in 2 and poor in 1 were obtained. Neither side effects such as allergic reactions nor abnormal findings in hematologic, hepatic and renal examinations were recognized.